Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population.

Abstract	Baloxavir, a cap-dependent endonuclease inhibitor, was recently approved for treatment of severe influenza infections. Combining baloxavir with oseltamivir has been proposed to increase the response rate. We report 2 hematopoietic cell transplant recipients with severe influenza infections who were treated with this combination and discuss possible reasons for their different responses.
Authors	Georgios Angelidakis, Fareed Khawaja, Victor E Mulanovich, Natalie Dailey-Garnes, Ella Ariza-Heredia, Roy F Chemaly
Journal	Microbes and infection (Microbes Infect) 2022 Apr-May Vol. 24 Issue 3 Pg. 104895 ISSN: 1769-714X [Electronic] France
PMID	34756990 (Publication Type: Journal Article)
Copyright	Copyright © 2021 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Chemical References	Antiviral Agents Dibenzothiepins Morpholines Pyridones Triazines Oseltamivir baloxavir
Topics	Antiviral Agents (therapeutic use) Dibenzothiepins Hematopoietic Stem Cell Transplantation (adverse effects) Humans Influenza, Human (drug therapy, epidemiology) Morpholines Oseltamivir (therapeutic use) Pyridones Transplant Recipients Triazines

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!